GlassScriptPhysician profile
Alberto O Barroso
NPI 1548335458
$7,597.84
in general payments reported to CMS, 2019-2025
31 companies · $1,636 in 2025
The $1,636 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,213 · 2020: $398 · 2021: $551 · 2022: $1,242 · 2023: $1,048 · 2024: $1,508 · 2025: $1,636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,109 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,109.12 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,658.91 | 2019-2025 | Rinvoq, Linzess, Creon |
| Boston Scientific Corporation | $647.76 | 2019-2023 | Axios, Exalt Model D |
| Janssen Biotech, INC. | $593.55 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $563.83 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $531.33 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $436.56 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $378.01 | 2019-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $315.31 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $258.82 | 2023-2025 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $112.73 | 2022 | |
| Celgene Corporation | $110.06 | 2022-2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $98.92 | 2019 | |
| Pharmacosmos Therapeutics INC. | $91.89 | 2023 | Monoferric |
| Olympus America INC. | $84.43 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $79.96 | 2019-2024 | Dificid |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $73.28 | 2024-2025 | Vegzelma |
| Braintree Laboratories, INC. | $72.23 | 2019-2024 | Sutab, Suflave |
| Ardelyx, INC. | $69.66 | 2022 | |
| Aimmune Therapeutics, INC. | $67.93 | 2024-2025 | Vowst |
| Daiichi Sankyo INC. | $53.34 | 2019-2023 | Injectafer |
| Shire North American Group INC | $53.04 | 2019 | |
| Lilly USA, LLC | $45.79 | 2024 | Omvoh |
| Covidien LP | $40.27 | 2019 | |
| Qol Medical, LLC | $36.45 | 2019-2022 | |
| Madrigal Pharmaceuticals | $27.36 | 2025 | Rezdiffra |
| Neuraxis, INC. | $21.07 | 2025 | |
| Alfasigma USA, INC. | $16.74 | 2020 | |
| Cook Medical LLC | $16.63 | 2022 | |
| Ferring Pharmaceuticals INC. | $16.46 | 2019 | |
| Novo Nordisk INC | $14.23 | 2022 | |
| Intercept Pharmaceuticals, INC. | $11.29 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alberto Barroso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.